PharmExec Direct eNewsletter

PharmExec Direct:
Having trouble viewing this e-mail? Click here.

You are subscribed to %%list.name%% as %%emailaddr%%.
Click here to unsubscribe or edit your member profile

PharmExec Direct | From the editors of Pharmaceutical Executive

July 23, 2010 | ISSUE NUMBER 158 VOL 8

FDA
Advisory Panel Rejects Avastin For Breast Cancer Treatment
Following the release of post-approval clinical studies, an FDA advisory committee determined that Roche’s cancer drug Avastin should not be used by patients being treated for metastatic breast cancer.

Advertisement:
Are You Really Closing the Loop?
There is a considerable advantage to being one of the first companies in pharma to successfully close the loop and pave the way to a new commercial model that puts the customer first. However, implementing comprehensive, closed-loop marketing has proven difficult for many in our industry. Capgemini Consulting examines the functional implications for implementing closed-loop marketing across the commercial organization and the hurdles to overcome to fully close the loop. Click here

Safety
Pfizer Suspends More Tanezunab Trials
Just weeks after ending tanezunab clinical studies in osteoarthritis patients, the drug giant is ceasing additional trials for two other indications.

Regulatory
Weight-Loss Drug Qnexa Loses in FDA Committee Ruling
Vivus’ Qnexa may help in weight loss, but it also now risks losing its place in the market following FDA’s Advisory Committee’s ruling July 15.

In The Magazine
Media Spend Trends
Pharma companies are starting to get back in the game with increased advertising spend in 2009. Do we have economic recovery to thank, or is there a deeper cause?

// Keryx Biopharmaceuticals appointed Joseph Feczko to its board of directors. // Chimerix named Timothy King vice president of clinical operations and Herve Mommeja-Marin vice president of clinical research. // James F. Young joined 3-V Biosciences’ board of directors. // David Moreira was appointed vice president of marketing at Menicon America. // Fibrocell Science added George J. Korkos to its board of directors. // Nycomed US named Steve Andrzejewski CEO. // The Foundation for the National Institutes of Health named Scott Campbell executive director and CEO.

Jul 26–27 Bio/Pharmaceutical Summit: Optimize Market Research and to Drive Accurate Product Forecasts
Philadelphia, PA

Jul 29–30 5th Annual Congress on Clinical Supply Chain Management
Princeton, NJ

Sep 9–10 Clinical Trials in Latin America
Lima, Peru

Sep 29–30 6th Annual Bio/Pharmaceutical and Medical Device Product Recalls Summit
Washington, DC

Dec 8—9 CMAC 2010 - Commercialization and Market Access Congress
Orlando, FL

A year and a half into President Obama's tenure, how do you view the effectiveness of the "new" FDA?

Abbott's PROGRESS Study of Kaletra and Isentress Meets the Primary Efficacy Endpoint.

Lilly Announces Completion of Alnara Acquisition

J&J Study Comparing Tapentadol Extended Release Tablets To Oxycodone Released

China’s Pharma Market: Friend or Foe?


	Follow Pharm Exec on Twitter
	Follow Pharm Exec on Facebook

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.